share_log

SC 13G: Statement of acquisition of beneficial ownership by individuals-AstraZeneca PLC(9.9%),AstraZeneca AB(9.9%)

SC 13G: Statement of acquisition of beneficial ownership by individuals-AstraZeneca PLC(9.9%),AstraZeneca AB(9.9%)

SC 13G：超過5%持股股東披露文件-AstraZeneca PLC(9.9%),AstraZeneca AB(9.9%)
美股SEC公告 ·  10/11 18:04

牛牛AI助理已提取核心訊息

AstraZeneca PLC, a global biopharmaceutical company, has filed a Schedule 13G with the United States Securities and Exchange Commission (SEC) on October 11, 2024, indicating a significant stake in Conduit Pharmaceuticals Inc. According to the filing, AstraZeneca PLC, through its wholly-owned subsidiary AstraZeneca AB, has acquired 9,504,465 shares of Conduit Pharmaceuticals' common stock, representing 9.9% of the company. This level of ownership makes AstraZeneca one of the major shareholders of Conduit Pharmaceuticals. The shares are directly held by AstraZeneca AB, and both AstraZeneca PLC and AstraZeneca AB are deemed to have sole voting and dispositive power over these shares. The percentage ownership was calculated based on 96,004,699 shares of Conduit Pharmaceuticals' common stock outstanding as of August 12, 2024. The filing was made under Rule 13d-1(c) of the Securities Exchange Act of 1934, which is used by persons who have acquired beneficial ownership of more than five percent of a class of equity securities of a publicly-traded company.
AstraZeneca PLC, a global biopharmaceutical company, has filed a Schedule 13G with the United States Securities and Exchange Commission (SEC) on October 11, 2024, indicating a significant stake in Conduit Pharmaceuticals Inc. According to the filing, AstraZeneca PLC, through its wholly-owned subsidiary AstraZeneca AB, has acquired 9,504,465 shares of Conduit Pharmaceuticals' common stock, representing 9.9% of the company. This level of ownership makes AstraZeneca one of the major shareholders of Conduit Pharmaceuticals. The shares are directly held by AstraZeneca AB, and both AstraZeneca PLC and AstraZeneca AB are deemed to have sole voting and dispositive power over these shares. The percentage ownership was calculated based on 96,004,699 shares of Conduit Pharmaceuticals' common stock outstanding as of August 12, 2024. The filing was made under Rule 13d-1(c) of the Securities Exchange Act of 1934, which is used by persons who have acquired beneficial ownership of more than five percent of a class of equity securities of a publicly-traded company.
全球生物製藥公司阿斯利康公司已在2024年10月11日向美國證券交易委員會（SEC）提交了一份13G表，表明在Conduit Pharmaceuticals公司擁有重要股權。根據申報文件，阿斯利康公司通過其全資子公司阿斯利康Ab已經收購了Conduit Pharmaceuticals的9504465股普通股，佔公司的9.9%。這一所有權水平使阿斯利康成爲Conduit Pharmaceuticals的主要股東之一。這些股份由阿斯利康Ab直接持有，阿斯利康公司和阿斯利康Ab都被視爲對這些股份擁有獨立投票和處理權。所佔百分比的所有權是基於截至2024年8月12日Conduit Pharmaceuticals普通股總量96004699股進行計算的。該申報是根據1934年證券交易法案第13d-1(c)規定進行的，該規定適用於已獲得公開上市公司某一類股權超過5%的實際受益所有者。
全球生物製藥公司阿斯利康公司已在2024年10月11日向美國證券交易委員會（SEC）提交了一份13G表，表明在Conduit Pharmaceuticals公司擁有重要股權。根據申報文件，阿斯利康公司通過其全資子公司阿斯利康Ab已經收購了Conduit Pharmaceuticals的9504465股普通股，佔公司的9.9%。這一所有權水平使阿斯利康成爲Conduit Pharmaceuticals的主要股東之一。這些股份由阿斯利康Ab直接持有，阿斯利康公司和阿斯利康Ab都被視爲對這些股份擁有獨立投票和處理權。所佔百分比的所有權是基於截至2024年8月12日Conduit Pharmaceuticals普通股總量96004699股進行計算的。該申報是根據1934年證券交易法案第13d-1(c)規定進行的，該規定適用於已獲得公開上市公司某一類股權超過5%的實際受益所有者。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間